Lead Sponsor

Catalysis SL

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

•Histological or clinical diagnosis of cirrhosis.
•HCV infection confirmed on a positive test for anti-HCV antibody and HCV RNA detectable in serum by Polymerase Chain Reaction.
•Patients who were non-responders to previous treatment with pegylated interferon and ribavirin or naïve patients with decompensated cirrhosis (Child-Pugh score ≥ 7) who had contraindicated the antiviral treatment.
•Presence of compensated or decompensated (Stage A, B or C according to the Child-Pugh Classification).
•Absence of clinical and ultrasonographic evidence of liver cancer, with α-fetoprotein levels ≤ 200 ng/ml.

•Age less than 18 or greater than 70 years.
•Presence of uncontrollable clinical or biochemical complications related to severe liver failure (hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, serum bilirubin level greater than 5 mg/dL, international normalized ratio greater than 2.5).
•Active alcoholism.
•Serum creatinine greater than 2 mg/dL.
•Hepatocellular carcinoma.
•Refusal to participate in the study.
•Concomitant disease with reduced life expectancy.
•Severe psychiatric conditions.
•Co-infection with hepatitis A or B or HIV.
•Drug dependence.
•Pregnancy.

Related studies

NCT07280390 · Cirrhosis, Microplastics, and more

NCT06345547 · Sarcopenia, Cirrhosis, and more

NCT07069725 · Liver Fibrosis, Hepatic Cirrhosis

NCT07439939 · Liver Cirrhosis, Portal Hypertension

NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.